Efficacy and Safety of Selpercatinib in Chinese Patients With RET Fusion-Positive Non-Small Cell Lung Cancer: A Phase 2 Trial

被引：0
|
作者：
Lu, S. [1 ]
Cheng, Y. [2 ]
Huang, D. [3 ]
Sun, Y. [4 ]
Wu, L. [5 ]
Zhou, C. [6 ]
Zhou, J. [7 ]
Guo, Y. [8 ]
Chen, L. [9 ]
Shao, J. [9 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Caner Ctr, Shanghai, Peoples R China
[2] Jilin Canc Hosp, Dept Thorac Oncol, Changchun, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Dept Thorac Oncol, Tianjin, Peoples R China
[4] Shandong Univ, Jinan Cent Hosp, Dept Oncol, Jinan, Peoples R China
[5] Hunan Canc Hosp, Dept Thorac Med 2, Changsha, Peoples R China
[6] Guangzhou Med Univ, State Key Lab Resp Dis, Natl Clin Res Ctr Resp Dis,Resp Med Dept, ffiliated Hosp 1,Guangzhou Inst Resp Hlth, Guangzhou, Peoples R China
[7] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Resp Dis, Hangzhou, Peoples R China
[8] Tongji Univ, Sch Med, Shanghai East Hosp, Dept Med Oncol, Shanghai, Peoples R China
[9] Eli Lilly & Co, Oncol, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
Selpercatinib; RET fusion-positive NSCLC; China; ORR;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA02.01
引用
收藏
页码：S888 / S889
页数：2
相关论文
共 50 条
  • [21] Updated Efficacy and Safety of Lorlatinib in a Phase 2 Study in Chinese Patients With Previously Treated Advanced ALK-Positive Non-small Cell Lung Cancer
    Lu, Shun
    Zhou, Qing
    Liu, Xiaoqing
    Du, Yingying
    Fan, Yun
    Cheng, Ying
    He, Shan
    Zhao, Huadong
    Li, Heyan
    Wu, Yi-Long
    CLINICAL LUNG CANCER, 2024, 25 (07)
  • [22] Phase III study of selpercatinib vs chemotherapy plus /- pembrolizumab in untreated RET positive non-small-cell lung cancer
    Solomon, Benjamin J.
    Zhou, Cai Cun
    Drilon, Alexander
    Park, Keunchil
    Wolf, Jurgen
    Elamin, Yasir
    Davis, Hannah M.
    Soldatenkova, Victoria
    Sashegyi, Andreas
    Lin, Aimee Bence
    Lin, Boris K.
    Loong, Herbert H.
    Novello, Silvia
    Arriola, Edurne
    Perol, Maurice
    Goto, Koichi
    Santini, Fernando C.
    FUTURE ONCOLOGY, 2021, 17 (07) : 763 - 773
  • [23] Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer
    Sakakibara-Konishi, Jun
    Takahashi, Hirofumi
    Ito, Kenichiro
    Ikari, Tomoo
    Ikezawa, Yasuyuki
    Kitai, Hidenori
    Furuta, Megumi
    Takashima, Yuta
    Shoji, Tetsuaki
    Fukudo, Masahide
    Konno, Satoshi
    RESPIRATORY MEDICINE CASE REPORTS, 2025, 53
  • [24] Clinicopathologic characteristics and diagnostic methods of RET rearrangement in Chinese non-small cell lung cancer patients
    Feng, Junnan
    Li, Yan
    Wei, Bing
    Guo, Lei
    Li, Weihua
    Xia, Qingxin
    Zhao, Chengzhi
    Zheng, Jiawen
    Zhao, Jiuzhou
    Sun, Rui
    Guo, Yongjun
    Brcic, Luka
    Hakozaki, Taiki
    Ying, Jianming
    Ma, Jie
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (04) : 617 - +
  • [25] Case Report: A case of ultra-late recurrence of KIF13A-RET fusion non-small cell lung cancer response to selpercatinib
    Park, Ha-Young
    Park, Joo-Heon
    Shin, Myung-Geun
    Han, Seung Jung
    Ji, Yong-Sok
    Oh, Hyung-Joo
    Kim, Young-Chul
    Lee, Taebum
    Choi, Yoo-Duk
    Oh, In-Jae
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [26] Combined Dacomitinib and Selpercatinib Treatment for a Patient with EGFR-Mutant Non-Small Cell Lung Cancer and Acquired CCDC6-RET Fusion
    Liu, Cheng-Yin
    Liu, Chia-Hsin
    ONCOTARGETS AND THERAPY, 2024, 17 : 499 - 506
  • [27] Treatment of non-small cell lung cancer with RET rearrangements
    Hoe, Hui Jing
    Solomon, Benjamin J.
    CANCER, 2025, 131
  • [28] Cost-effectiveness analysis of selpercatinib versus chemotherapy and pembrolizumab in the first-line treatment of rearranged during transfection fusion-positive non-small cell lung cancer in the United States
    Yi, Hongbin
    Cao, Yingdan
    Shi, Fenghao
    Wei, Xiaoxia
    Han, Sheng
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2024, 46 (06) : 1427 - 1435
  • [29] Efficacy and safety analysis of immunotherapy in non-small cell lung cancer patients with MET alterations
    Wang, Yanhua
    Wei, Jingwen
    Xu, Manyi
    Xiang, Jing
    Shao, Keda
    Hao, Yue
    Song, Zhengbo
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (10) : 2503 - 2512
  • [30] Current management of RET rearranged non-small cell lung cancer
    Stinchcombe, Thomas E.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
12345